Sample Collection and Laboratory Analysis Sample Clauses

Sample Collection and Laboratory Analysis. Wood will collect samples at 23 stormwater lakes and three pump stations each month for one year. The sample collection schedule will be coordinated according to the City of Naples Naples Bay water quality monitoring. In- situ water quality measurements will be recorded alongside sample collection and will include temperature, pH, dissolved oxygen (mg/L and % saturation), and conductivity/salinity. Water quality meters (i.e. YSI) will be calibrated and maintained according to FDEP SOPs. Samples will be collected according to FDEP SOPs. After proper preservation (i.e. acidification or filtration) immediately after collection, samples will be placed on ice and transported to the analytical laboratory within analytical hold times. To meet QA/QC requirements, Wood will collect one equipment blank per monthly event for all parameters except fecal indicator bacteria, biological (chlorophyll-a), and physical/aggregate parameters (hardness, color, turbidity). Total Kjeldahl Nitrogen 351.2 0.05 mg/L Nitrate + Nitrite Nitrogen Systea 1-reagent 0.006 mg/L Nitrite SM4500-NO2B 0.003 mg/L Nitrate Calculation 0.006 mg/L Ammonia Nitrogen 350.1 0.008 mg/L Total Nitrogen Calculation 0.05mg/L Total Phosphorus 365.3 0.008 mg/L Total Hardness SM2340C 0.682 mg/L Color/pH SM2120B 2.5 CU Turbidity 180.1 0.11 NTU Ortho-Phosphorus 365.3 0.002 mg/L Total Suspended Solids SM2540D 0.570 mg/L Copper SM3113B/MIBK 0.346/0.271 mg/L Chlorophyll a* 445.0 0.25 ug/L Fecal Coliform (MF) SM2540C #/100 xX X.coli (MPN) SM9223B (quantitray) #/100 mL Enterococci EPA 1600 #/100 mL *Stormwater lake sample only Samples will be collected in one day using two sampling teams. The two teams will work separate routes, splitting the sampling and coordinating a single lab drop off for the end of the day. Wood also obtained quotes from two analytical laboratories: Benchmark EnviroAnalytical, Inc. (Benchmark) and Xxxxxxx Laboratories, Inc. (Xxxxxxx), included in Attachment B. The monthly analytical costs for the parameters in Table 1 were $5,626.50 from Benchmark and over $9,000 from Xxxxxxx, which translated into an almost $50,000 difference over a one-year period. Therefore, only the Benchmark analytical costs are included in the fee schedule (Attachment A). It should be noted that the per sample cost for each parameter were higher for both noted labs as compared to Advanced Environmental Laboratories, Inc. (AEL). However, upon direction from the City, AEL quotes were not included as part of this proposal.
Sample 1Sample 2
AutoNDA by SimpleDocs
Sample Collection and Laboratory Analysis. 4.1.1 The purpose of the elutriate test is to simulate the release of dissolved contaminants from dredging operations. 4.1.2 The elutriate test requires the collection of ambient water for mixing with sediment samples for analysis. Blank seawater samples will be used and analysed to study the concentration of contaminates released from the sediment. 4.1.3 The testing parameters, analytical methods, reporting limits and QA/QC procedures for the elutriate test are listed in Table 4-1. Standard elutriate preparation for sediment and marine water samples will be carried out in accordance with “Evaluation of Dredged Material Proposed for Ocean Disposal – Testing Manual, USEPA and US Army Corps of Engineers, EPA 503/8- 91/001, 1991” and “Evaluation of Dredged Material Proposed for Discharge on Waters of the US – Testing Manual (Inland Testing Manual), USEPA and US Army Corps of Engineers, EPA 823-B-98/004, 1998”. Cadmium (Cd) ICP-MS USEPA 6020A 0.2 µg /L Chromium (Cr) ICP-MS USEPA 6020A 1 µg /L Copper (Cu) ICP-MS USEPA 6020A 1 µg /L Mercury (Hg) ICP-AES/CV-AAS USEPA 6010B/ APHA 3112B 0.1 µg /L Nickel (Ni) ICP-MS USEPA 6020A 1 µg /L Lead (Pb) ICP-MS USEPA 6020A 1 µg /L Silver (Ag) ICP-MS USEPA 6020A 1 µg /L Zinc (Zn) ICP-MS USEPA 6020A 4 µg /L Metalloid (µg/L) Arsenic (As) ICP-MS USEPA 6020A 2 µg /L Organic PAHs (µg/L) Low Molecular Weight PAHs GC-MSD USEPA 3510C or 3630C or 8270C 0.2 µg /L High Molecular Weight PAHs Organic Non-PAHs (µg/L) Total PCBs GC-ECD/GC-MSD USEPA 3510C or 3630C or 8270C 0.01 µg /L Organometallics (µg TBT/L in interstitial water) Tributylin (TBT) GC-MSD UNEP / IOC / IAEA (2) 0.015 µg /L Chlorinated Pesticides (µg/L) Alpha-BHC Beta-BHC Gamma-BHC Delta-BHC Heptachlor Aldrin Heptachlor epoxide Endosulfan p,p’-DDT p,p’-DDD p,p’-DDE Endosulfan sulfate GCMSD/ GCECD USEPA 3510C USEPA 3620B USEPA 8270C USEPA 8081A 0.1 µg /L (individually) Ammonia FIA APHA 4500-NH3 H 0.025mg/L Nitrite as N FIA APHA 4500-NO3 I 0.025mg-/L Nitrate as N FIA APHA 4500-NO3 I 0.025mg-/L Total Kjeldahl Nitrogen (TKN) Kjeldahl APHA 4500-Norg + NH3 C 0.05 mg-/L Total P Colorimetric APHA 4500-PB&E 0.02 mg-/L Reactive P FIA APHA 4500-PF 0.01 mg-/L Remarks: (1) Low molecular weight PAHs include acenaphthene, acenaphthylene, anthracene, fluorene, naphthalene, and phenanthrene; High molecular weight PAHs include benzo[a]anthracene, benzo[a]pyrene, chrysene, dibenzo[a,h]anthracene, fluoranthene, pyrene, benzo[b]fluoranthene, benzo[k]fluoranthene, indeno[1,2,3-c,d]pyrene and benzo[...
Sample 1
Sample Collection and Laboratory Analysis. Sediment cores would be collected using a vibracore by Anchor QEA and our subcontractor Leviathan Environmental Services from 13 locations within three dredge units. Enough sediment would be collected and archived to characterize sediments for in-Bay disposal or placement at Montezuma according to the approved SAP. Reference sediment would be collected from the SF-9 reference site. Individual core samples and Z-layer samples would be archived from each core. Depending on composite sediment chemistry results, limited chemical analysis of these samples may be required. An individual core sample would only be analyzed if there is a need to refine the dredge areas based on elevated chemistry values. A Z-layer sample would only be analyzed to characterize the newly exposed surface layer if the dredged sediment exhibited elevated chemical concentrations. These additional analyses would only be conducted if requested by DMMO. Additional analysis of individual core samples and Z-layer samples is not included in this cost estimate. In accordance with DMMO guidelines, three composite samples would be submitted for physical and chemical analyses and biological testing to determine suitability for in-Bay disposal and placement at Montezuma. Sediment chemistry would include total solids, total organic carbon, grain size, metals, organotins, polycyclic aromatic hydrocarbons, organochlorine pesticides, and polychlorinated biphenyls. Biological testing for in-Bay disposal would include two solid phase tests and one suspended particulate phase test. During solid phase biological testing, reference sediment would be tested concurrently with composite samples for comparative purposes. Additional analysis for placement at Montezuma would include modified elutriate chemistry and bioassay testing. Anchor QEA would perform data validation to ensure laboratory analyses meet the project data quality objectives.
Sample 1

Related to Sample Collection and Laboratory Analysis

  • Escrow Analysis If applicable, with respect to each Mortgage Loan, the Seller has within the last twelve months (unless such Mortgage was originated within such twelve month period) analyzed the required Escrow Payments for each Mortgage and adjusted the amount of such payments so that, assuming all required payments are timely made, any deficiency will be eliminated on or before the first anniversary of such analysis, or any overage will be refunded to the Mortgagor, in accordance with RESPA and any other applicable law;

  • Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall: (a) supervise all aspects of the operations of the Funds; (b) obtain and evaluate pertinent information about significant developments and economic, statistical and financial data, domestic, foreign or otherwise, whether affecting the economy generally or the Funds, and whether concerning the individual issuers whose securities are included in the assets of the Funds or the activities in which such issuers engage, or with respect to securities which the Advisor considers desirable for inclusion in the Funds' assets; (c) determine which issuers and securities shall be represented in the Funds' investment portfolios and regularly report thereon to the Board of Trustees; (d) formulate and implement continuing programs for the purchases and sales of the securities of such issuers and regularly report thereon to the Board of Trustees; and (e) take, on behalf of the Trust and the Funds, all actions which appear to the Trust and the Funds necessary to carry into effect such purchase and sale programs and supervisory functions as aforesaid, including but not limited to the placing of orders for the purchase and sale of securities for the Funds.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Search, Enquiry, Investigation, Examination And Verification a. The Property is sold on an “as is where is basis” subject to all the necessary inspection, search (including but not limited to the status of title), enquiry (including but not limited to the terms of consent to transfer and/or assignment and outstanding charges), investigation, examination and verification of which the Purchaser is already advised to conduct prior to the auction and which the Purchaser warrants to the Assignee has been conducted by the Purchaser’s independent legal advisors at the time of execution of the Memorandum. b. The intending bidder or the Purchaser is responsible at own costs and expenses to make and shall be deemed to have carried out own search, enquiry, investigation, examination and verification on all liabilities and encumbrances affecting the Property, the title particulars as well as the accuracy and correctness of the particulars and information provided. c. The Purchaser shall be deemed to purchase the Property in all respects subject thereto and shall also be deemed to have full knowledge of the state and condition of the Property regardless of whether or not the said search, enquiry, investigation, examination and verification have been conducted. d. The Purchaser shall be deemed to have read, understood and accepted these Conditions of Sale prior to the auction and to have knowledge of all matters which would have been disclosed thereby and the Purchaser expressly warrants to the Assignee that the Purchaser has sought independent legal advice on all matters pertaining to this sale and has been advised by his/her/its independent legal advisor of the effect of all the Conditions of Sale. e. Neither the Assignee nor the Auctioneer shall be required or bound to inform the Purchaser of any such matters whether known to them or not and the Purchaser shall raise no enquiry, requisition or objection thereon or thereto.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Money Market Fund Compliance Testing and Reporting Services Subject to the authorization and direction of the Trust and, in each case where appropriate, the review and comment by the Trust’s independent accountants and legal counsel, and in accordance with procedures that may be established from time to time between the Trust and the Administrator, the Administrator will:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!